Akili Interactive Labs raises $160M in equity and debt to transform cognitive healthcare via prescription videogame treatments

Akili raises $110m to build its digital therapeutics pipeline (pharmaforum): EndeavorRx became the first and so far only approved prescription video game treatment in the US when it was cleared by the FDA last year to treat attention-deficit hyperactivity disorder (ADHD), and has also been given a green light in Europe. It is also being tested for other indications including fuzzy thinking in COVID-19 survivors, a condition sometimes known as ‘brain fog’. The new funding, which is accompanied by a $50 million loan facility, is earmarked for the continued rollout of the app as well as Akili’s pipeline of prescription digital therapeutics for “a range of chronic and acute cognitive disorders,” said the Boston-based company. The Series D was led by Neuberger Berman Funds and included a string of other investors, including venture capital arms of drugmakers like Shionogi, Amgen and Merck KGaA … Other programmes in the R&D phase are targeting cognitive dysfunction in depression and multiple sclerosis, autism spectrum disorder, a cognitive assessment tool and a gaming app that combines cognitive and physical training. The Announcement: Akili Secures $160 Million in Financing; Poised to Deliver on the Promise of Digital Therapeutics (press release): … This funding will support a go-to market approach that brings EndeavorRx to families and healthcare professionals at scale and expand Akili’s global footprint within attention-deficit/hyperactivity disorder (ADHD) a...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Attention & ADD/ADHD Brain/ Mental Health Technology & Innovation Akili Akili Inter­ac­tive Labs attention deficit hyperactivity disorder cognitive healthcare cognitive--disorders digital therapeutics EndeavorRx FDA Neuberger Berma Source Type: blogs